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Stem-like glioma cells reside within a perivascular
niche and display hallmark radiation resistance. An
understanding of the mechanisms underlying these
properties will be vital for the development of effec-
tive therapies. Here, we show that the stem cell
marker CD44 promotes cancer stem cell phenotypes
and radiation resistance. In amousemodel of glioma,
Cd44/ andCd44+/ animals showed improved sur-
vival compared to controls. The CD44 ligand osteo-
pontin shared a perivascular expression pattern
with CD44 and promoted glioma stem cell-like phe-
notypes. These effects were mediated via the g-sec-
retase-regulated intracellular domain of CD44, which
promoted aggressive glioma growth in vivo and
stem cell-like phenotypes via CBP/p300-dependent
enhancement of HIF-2a activity. In human glioblas-
toma multiforme, expression of CD44 correlated
with hypoxia-induced gene signatures and poor sur-
vival. Altogether, these data suggest that in the
glioma perivascular niche, osteopontin promotes
stem cell-like properties and radiation resistance in
adjacent tumor cells via activation of CD44 signaling.
INTRODUCTION
Despite intensive treatment with surgery, radiation, and chemo-
therapy, glioblastoma multiforme (GBM)—the highest-grade gli-
oma and most aggressive brain tumor—invariably recurs as an
incurable lesion (Huse and Holland, 2010). Recurrence is tightly
coupled to increased resistance to radiation and chemotherapy,
hallmark features of stem-like glioma cells (Pietras, 2011). Stem-
like glioma cells have been enriched experimentally based on
expression of stem cell markers such as CD133 (Singh et al.,C2003) and CD44 (Anido et al., 2010) or their ability to exclude
Hoechst dye in the side population (SP) assay (Bleau et al.,
2009) and are characterized by self-renewal ability, stem cell
marker expression, and resistance to radiation. Like stem cells
in the normal brain subventricular zone, stem-like glioma cells
reside in a perivascular niche (PVN) thought to maintain the
stem cell character of adjacent tumor cells (Calabrese et al.,
2007). Indeed, we previously showed that nitric oxide from
PVN endothelial cells activates Notch signaling in glioma cells,
leading to increased stem cell characteristics (Charles et al.,
2010). Thus, understanding how niche factors are involved in
maintaining aggressive glioma cell phenotypes may help identify
novel potential targets for enhancing the efficacy of cancer
therapeutics.
CD44, a glycoprotein transmembrane receptor, is a marker of
stem cells from a variety of normal and neoplastic tissues (Zo¨ller,
2011). As a receptor for extracellular matrix components such as
hyaluronic acid (HA) and osteopontin (OPN), most described
functions for CD44 are as an adhesion molecule. CD44-medi-
ated adhesion is thought to be important, among other things,
for stem cell homing to the niche, and indeed both HA and
OPN have been described as components of stem cell niches
(Haylock and Nilsson, 2005). Beyond adhesion, CD44 itself can
act as an intracellular signaling molecule. The C-terminal intra-
cellular domain (CD44ICD) initiates signaling by interacting with
proteins like c-Src while membrane bound (Bourguignon et al.,
2001). In addition, CD44 is subject to proteolytic activation
similar to that of Notch receptors: extracellular cleavage fol-
lowed by g-secretase-dependent release of CD44ICD (Mura-
kami et al., 2003; Nagano et al., 2004; Nagano and Saya,
2004; Okamoto et al., 2001). Once released, CD44ICD localizes
to both the cytoplasm and nucleus, but the mechanisms under-
lying its signaling as well as its functions remain poorly
understood.
In glioma, CD44 is expressed highly in the mesenchymal sub-
type of GBM (Phillips et al., 2006), and its expression has been
used to enrich for stem-like cells (Anido et al., 2010). Here, we
found that Cd44/ and Cd44+/ mice survived longer thanell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc. 357
Figure 1. Cd44 Contributes to Aggressive
Growth in aMouseModel of Proneural GBM
(A and B) Hematoxylin and eosin and CD44
stainings by IHC of murine PDGFB-induced
gliomas in a Cd44+/+ (A) and Cd44/ (B) back-
ground.
(C) PDGFB-inducedmurine gliomas fromCd44+/+,
Cd44+/, and Cd44/ backgrounds were classi-
fied as low or high grade based on histological
features. Data represent percentage of tumors
within each background that were high and low
grade. p < 0.001.
(D) Kaplan-Meier plot of survival with tumors for
Cd44+/+ (n = 10), Cd44+/ (n = 16), and Cd44/
(n = 10) Ntv-a mice injected with RCAS-PDGFB
virus. *p < 0.05, **p < 0.01, ***p < 0.001 (log-rank
[Mantel-Cox] test).
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gliomas, indicating that CD44 actively contributes to aggressive
glioma growth. We found that the CD44 ligand OPN shared a
perivascular expression pattern with CD44 in PDGF-driven gli-
oma and OPN enhanced stemness of glioma cells, including
increasing the SP and radiation resistance. CD44ICD was suffi-
cient to induce these stem cell characteristics in glioma cells
and potentiated aggressive tumor growth in PDGF-induced
gliomas in vivo. We found that CD44ICD enhanced hypoxia-
inducible factor 2a (HIF-2a) function in a CBP/p300-dependent
manner and HIF-2a mediated downstream effects of CD44ICD
on stemness. In human GBM, CD44 expression correlated
with aggressive growth and poor survival in the proneural sub-
type and CD44 expression was significantly correlated with
hypoxia-induced gene signatures. Taken together, our data
identify OPN as a stem cell-promoting extracellular factor in
the GBM PVN and demonstrate that CD44 signaling via its
intracellular domain promotes aggressive growth and stem cell
characteristics by enhancing HIF-2a activity.
RESULTS
Cd44 Contributes to Aggressive Tumor Growth in
Proneural GBM
Proneural GBM is characterized by elevated PDGF receptor
signaling and can be modeled by overexpressing PDGF in
Nestin-expressing stem cells in the mouse brain. Specifically,
we employed the RCAS/tv-a system (Holland et al., 1998) and in-
fectedNestin-tv-a (Ntv-a) mice in a wild-type (generating a spec-
trum of low- to high-grade gliomas) or Ink4a/Arf/ (generating
exclusively GBM) background with RCAS-PDGF. The resulting
tumors displayed minimal detectable CD44 expression in the
tumor bulk and high-restricted expression in cells of the PVN
(Figure 1A). We then generated gliomas in Ntv-a mice crossed
into a Cd44/ and Cd44+/ background. The resulting gliomas
were largely indistinguishable from Cd44+/+ tumors by hematox-
ylin and eosin staining but lacked any evidence of CD44 expres-358 Cell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc.sion (Figure 1B). Wild-type tumors were
scored as either low- or high-grade gli-
omas based on histological features.
Interestingly, in the Ntv-a Ink4a/Arf+/+background, Cd44+/+ animals developed significantly more
high-grade gliomas compared to Cd44+/ and Cd44/ mice
(Figure 1C). In the Ntv-a Ink4a/Arf/ background, there was a
significant survival difference between groups, with Cd44+/+
(n = 10) tumors being the most aggressive, Cd44/ (n = 10)
the least aggressive, and Cd44+/ (n = 16) tumors falling in
between (Figure 1D). These data support that CD44 actively
contributes to tumor aggressiveness in proneural GBM.
The CD44 Ligand OPN Is Restricted to the PVN and
Promotes Stemness in Proneural GBM
We next stained murine gliomas for CD44 and the CD44 ligand
OPNby dual immunofluorescence and found perivascular coloc-
alization of OPN andCD44with little detectable expression in the
tumor bulk (Figure 2A), suggesting that OPN could bind CD44 in
the proneural GBMPVN. Because of the PVN localization of OPN
and CD44 and because CD44 is a marker of stem-like cells, we
asked whether activation of CD44 by OPN could induce the
stem-like phenotype. Throughout the study, we chose two func-
tional assays with clear clinical implications, the drug efflux-
based SP assay that was previously demonstrated to enrich
for stem-like tumor-initiating cells in human and murine glioma
(Bleau et al., 2009; Golebiewska et al., 2011) and the colony-
formation assay following irradiation, in addition to expression
of a panel of well-established stem cell markers (Nanog, Sox2,
Oct4, and Id1), for a broad and relevant measure of stemness.
First, culturing PDGF-induced glioma primary cultures (PIGPCs),
human U251, and human T98G glioma cells in the presence of
400 ng/ml OPN for 48 hr induced an increase in the SP (Fig-
ure 2B). Conversely, treating PIGPCs with the IM7 anti-CD44
blocking antibody that blocks CD44-ligand interactions, in-
cluding that of CD44 and OPN (Weiss et al., 2001), resulted in
a marked decrease in the SP (Figure 2C), suggesting that
CD44 function is necessary for the SP phenotype. CD44 block-
ing similarly reduced the SP of primary human proneural GBM
cells and primary murine GBM neurosphere cultures (Figure 2C).
Of note, Cd44 levels were significantly higher in sorted SP cells
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online). Second, the stem cell markers Nanog, Sox2, Oct4, and
Id1 were all upregulated in OPN-treated PIGPCs as well as pri-
mary human GBM cells, as shown by quantitative real-time
PCR (qPCR) (Figures 2D and 2E). Finally, PIGPCs treated with
OPN formed more colonies than control cells in a colony-forma-
tion assay following a single dose of 2 Gy irradiation (Figure 2F).
Together, these data suggest that OPN acts as a PVN factor to
induce the stem-like state of PVN GBM cells. We next tested
the tumor-initiating capacity of PIGPCs pretreated or not with
OPN in vitro prior to intracranial injection in recipient mice and
found no significant difference between groups in tumor forma-
tion or survival (Figure S1B). These data are in line with recent
advances separating stemness from tumor-initiating ability spe-
cifically in GBM (Barrett et al., 2012).
CD44 can be activated by proteolytic cleavage in a two-step
process dependent on g-secretase, resulting in the release of
a CD44 intracellular domain (CD44ICD). Because of the well-
documented inhibitory effects of g-secretase inhibition on brain
tumor stemness (at least partially mediated through inhibition of
Notch) (Fan et al., 2006), we speculated that CD44ICD release
may be involved downstream of OPN. To test this hypothesis,
we treated PIGPCs with OPN in the presence of a g-secretase
inhibitor (GSI; MK-003) or control and measured expression of
our panel of stem cell markers. Notably, g-secretase inhibition
was sufficient to inhibit the effect of OPN on either marker in
the panel (Figure 2G), suggesting that g-secretase-dependent
release of CD44ICD could indeed be involved downstream of
OPN-CD44. To test whether cleavage of CD44 is induced by
OPN, we blotted for CD44 using an antibody recognizing the
C-terminal end of the protein. Because this antibody recognizes
human CD44, we utilized human U251 glioma cells. Tetradeca-
noyl phorbol acetate (TPA), an activator of protein kinase C
and the best-described inducer of CD44ICD generation, was
used to generate a positive control sample, and TPA treatment
in combination with g-secretase inhibitor was used as a negative
control. As expected, TPA induced a CD44 band slightly smaller
than 15 kDa corresponding to CD44ICD (Figure 2H). TPA in com-
bination with g-secretase inhibitor diminished this band and
instead resulted in accumulation of a band slightly larger than
15 kDa corresponding to CD44EXT (CD44 after extracellular
cleavage, before CD44ICD release). OPN treatment of U251
cells also resulted in increased CD44ICD release as compared
to untreated control after 24 hr (Figure 2H, long exposure). Quan-
tification of band intensities across several experiments revealed
on average a 2-fold significant induction of CD44ICD by OPN
treatment (Figure 2H).
CD44ICD Promotes Aggressive Growth in PDGF-
Induced GBM
An intracellular role for CD44 in gliomawas supported by staining
murine gliomas with an antibody detecting C-terminal CD44.
Stainings revealed cells with CD44 expression in the nucleus
(left panel, black arrow), membrane (middle panel, white arrow),
and cytoplasm (right panel, gray arrow) (Figure 3A), indicating
that CD44 expression reflects the potential to be spontaneously
activated in vivo. To study effects of CD44ICD release more
carefully, we created a fusion protein with enhanced green fluo-
rescent protein (EGFP) fused to the human CD44ICD N terminusC(EGFP-CD44ICD; Figure 3B). When expressed in PIGPCs,
EGFP-CD44ICD localized throughout the cell in both the cyto-
plasm and the nucleus (Figure 3C). We inserted the EGFP-
CD44ICD fusion gene into the RCAS vector and injected N-tva
Ink4a/Arf/ mice with RCAS-PDGF in combination with either
RCAS-EGFP-CD44ICD or RCAS-GFP to study effects of
CD44ICD in glioma in vivo. Tumors formed after coinjection of
PDGFB with EGFP-CD44ICD contained a larger proportion
of cells staining positive for intracellular/nuclear CD44 as
detected by immunohistochemistry (IHC) with an antibody
recognizing the C-terminal end and quantified using ImageJ
(Figure 3D; Figure S2). Importantly, PDGFB/EGFP-CD44ICD-
induced tumors were more aggressive, because mice injected
with PDGFB/GFP (n = 8) survived significantly longer than those
injected with PDGFB/EGFP-CD44ICD (n = 6) (Figure 3E). These
data indicate that CD44ICD alone can contribute to aggressive
tumor growth in glioma. Together with the finding that mice
with Cd44/ GBM survived longer than those with Cd44+/+
GBM (Figure 1D), these data further establish CD44 as an active
contributor to aggressive growth in PDGF-induced GBM.
CD44ICD Promotes Glioma Stemness
To test whether CD44ICD alone could mimic the phenotype
induced by OPN, we expressed EGFP-CD44ICD or control in a
TetOn doxycycline (Dox)-inducible system where CD44ICD
expression could be rapidly controlled in T98G glioma cells
and subjected them to the same analyses to quantify stemness
as in the OPN set of experiments. First, EGFP-CD44ICD expres-
sion resulted in a 4-fold increase in the SP as compared to
EGFP-expressing controls (Figure 4A), indicating that CD44ICD
is sufficient to induce the SP phenotype in a subset of glioma
cells. CD44ICD expression similarly increased the SP of PIGPCs
(Figure 4A). To test whether effects of CD44 blockade could be
rescued by CD44ICD, we expressed CD44ICD stably in PIGPCs.
Importantly, PIGPCs expressing EGFP-CD44ICD no longer
underwent reduction of the size of SP by CD44-blocking anti-
bodies as shown earlier (Figure 4B), strongly arguing that
CD44 blockade acts by inhibiting the release of CD44ICD. Sec-
ond, we tested whether expression of CD44ICD could induce
expression of our panel of stem cell markers. Indeed, Nanog,
Sox2, Oct4, and Id1 expression was increased by CD44ICD
expression in PIGPCs, primary human GBM cells, and human
U251 glioma cells (Figures 4C–4E). NANOG and SOX2 expres-
sion was significantly induced by EGFP-CD44ICD in T98G cells,
whereas expression of OCT4 and ID1 was unaffected in this cell
line (Figure 4F). Finally, we tested the colony-forming ability of
cells expressing EGFP-CD44ICD after a single dose of irradia-
tion. After 1, 2, or 4 Gy irradiation, EGFP-CD44ICD-expressing
T98G cells formed more colonies than controls (Figure 4G),
thus again mimicking the effect of OPN. Together, these data
indicate that CD44ICD can drive parts of the stem cell phenotype
in the PVN of PDGF-induced GBM.
CD44ICD Acts by Enhancing HIF-2a Activity
Saya and colleagues demonstrated that CD44ICD could poten-
tiate transactivation mediated by the transcriptional coactivator
CBP/p300 (Okamoto et al., 2001). Although CBP/p300 can
potentiate transcription by a wide range of transcription factors,
one such family of CBP/p300-dependent transcription factorsell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc. 359
(legend on next page)
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factors (HIFs) (Li et al., 2009; Pietras et al., 2010; Semenza,
2007). We speculated that CD44ICD promoted stemness by
enhancing HIF-dependent transcription and transfected T98G
cells expressing EGFP or EGFP-CD44ICD with a hypoxia-
responsive element (HRE)-luciferase reporter in the presence
of control or the hypoxia-mimetic 2,2-dipyridyl (DIP) to stabilize
HIFs. DIP-treated EGFP-expressing cells displayed on average
a 10-fold induction of HRE-luciferase as compared to control
cells (Figure 5A). Strikingly, EGFP-CD44ICD-expressing cells
treated with DIP indeed had a 2- to 3-fold-higher induction of
HRE-luciferase as compared to DIP-treated control cells (Fig-
ure 5A), thus supporting the hypothesis that CD44ICD potenti-
ated HIF activation. Similarly, CD44ICD expression significantly
enhancedHRE activation even at normoxic conditions in primary
human proneural GBM cells and U251 glioma cells (Figures 5B
and 5C). DIP stabilizes both HIF-1a and HIF-2a, so to elucidate
whether this potentiation was dependent on HIF-1a, HIF-2a, or
both, we overexpressed oxygen-insensitive versions of the
HIFs (Yan et al., 2007) together with EGFP or EGFP-CD44ICD.
In EGFP-expressing control cells, HIF-1a and HIF-2a both
induced the HRE-luciferase reporter to a similar extent (Fig-
ure 5D). Intriguingly, however, CD44ICD potentiated induction
of HRE-luciferase only together with HIF-2a, with no potentiation
of HIF-1a-dependent HRE-activation in T98G cells (Figure 5D). In
U251 cells, in contrast, CD44ICD enhanced HRE activation both
by HIF-1a and HIF-2a (Figure 5E). However, knocking down
HIF1A (Figure S4A) in U251 cells by small interfering RNA (siRNA)
had no effect on the potentiated HRE activation by CD44ICD,
whereas knockdown of HIF2A entirely diminished the difference
between EGFP and CD44ICD-expressing cells (Figure 5F), indi-
cating that even in these cells, HIF2A was the primary HIF
involved in CD44ICD signaling. Finally, genes of the stemness
panel were induced by hypoxia in a HIF2A-dependent manner
in U251 cells (Figure S3). To test whether HIF-2a mediated the
stemness-promoting effect of CD44ICD, we treated T98G
TetOn-CD44ICD cells with control or two independent siRNAs
targeting HIF2A (Figure S4B) and then cultured them with either
DIP (to stabilize HIFs) or Dox (to induce CD44ICD expression).
DIP treatment induced mRNA expression of the CD44ICD-
induced stem cell markers SOX2 and NANOG (Figure 5G). ThisFigure 2. OPN Is Expressed in the PVN and Induces a Stem-like Pheno
(A) Dual immunofluorescence of CD44 (green) and OPN (red) on DAPI (blue)-stai
(B) SP analysis of PIGPCs, U251, and T98G cells cultured with or without 400 ng
graphs show relative SP from at least three separate experiments.
(C) SP analysis of PIGPCs, primary humanGBM cultures, and primarymurine neur
antibodies for 72 hr prior to analysis. Right graphs show relative SP from at leas
(D) Quantitative PCR (qPCR) data for relative mRNA expression of Nanog, Sox2,
represent average values of at least three independent experiments. Error bars r
(E) qPCR data for relative mRNA expression of NANOG, SOX2, OCT4, and ID1 in
Data represent average values of at least three independent experiments. Error
(F) Fraction survival of PIGPCs treated with or without OPN at day 7 in a colony-f
*p < 0.05; ns, not significant (Student’s t test).
(G) qPCR data for relative mRNA expression ofNanog, Sox2,Oct4, and Id1 in PIGP
003 (GSI) as indicated. Data represent one representative experiment out of at lea
significant (Student’s t test).
(H) Western blot analysis of CD44 and tubulin in U251 cells treated as indicated w
TPA with 10 mM MK-003 (GSI) (negative control for CD44ICD) as indicated. CD4
shows quantification of CD44ICD signal across three independent experiments.
See also Figures S1 and S7.
Cinduction was mediated by HIF-2a, because DIP did not induce
these genes in HIF2A-knockdown cells (Figure 5G). Importantly,
SOX2 and NANOG induction by CD44ICD (Figure 4F) was also
HIF-2a dependent, because knockdown of HIF2A abrogated
any effect of CD44ICD on these genes (Figure 5G). Expression
of the stem cell markers OCT4 and ID1, which were not induced
by CD44ICD in T98G cells (Figure 4F), was unaffected both by
DIP and Dox treatment in these cells (Figure 5G). We further
tested expression of the well-described hypoxia-induced gene
VEGF. As expected, VEGF was induced by DIP. However, this
induction was not mediated by HIF-2a, because HIF2A knock-
down did not affect VEGF induction by DIP (Figure 5H). In agree-
ment with CD44ICD acting through HIF-2a, CD44ICD induction
did not affect VEGF expression (Figure 5H).
We next asked whether the induction of SP by CD44ICD was
also dependent on HIF-2a and again treated cells transfected
with siRNAs targeting HIF2A or control, with or without Dox.
SP analysis revealed that whereas cells expressing nontargeting
control siRNA induced the SP upon EGFP-CD44ICD expression,
cells transfected with two independent siRNAs targeting HIF2A
did not (Figure 5I). Taken together, these data establish
CD44ICD as an enhancer of HIF-2a function and demonstrate
that the stemness-promoting effects of CD44ICD are mediated
by HIF-2a in these cells.
CD44ICD Potentiates HIF-2a in a CBP/p300-Dependent
Manner
To investigate the mechanism by which CD44ICD enhanced
HIF-2a, we treated T98G TetOn-CD44ICD cells with DIP (to sta-
bilize HIFs) and/or Dox (to induce CD44ICD expression) and
measured HIF2A mRNA levels. Neither DIP nor Dox resulted in
significantly alteredHIF2A transcript levels (Figure 6A; Figure S5).
On the other hand, T98G TetOn-CD44ICD cells expressed
higher HIF-2a protein levels when treated with both DIP and
Dox together as compared to DIP alone (Figure 6B), suggesting
that CD44ICD helps stabilize HIF-2a by inhibiting degradation
rather than by increased transcription. Because CD44ICD was
previously demonstrated to potentiate CBP/p300-mediated
transcription, we speculated that CD44ICD potentiation of
HIF-2awas dependent on CBP and/or p300. To test this hypoth-
esis, we transfected siRNAs targeting control, CBP, or p300type in Cultured Glioma Cells
ned PDGFB-induced murine glioma.
/ml OPN as indicated for 48 hr. Inset shows FTC-treated control sample. Right
osphere cultures treated with immunoglobulin G control or anti-CD44-blocking
t three separate experiments.
Oct4, and Id1 in PIGPCs treated with or without 400 ng/ml OPN for 24 hr. Data
epresent SEM. *p < 0.05, **p < 0.01 (Student’s t test).
primary human GBM cultures treated with or without 400 ng/ml OPN for 24 hr.
bars represent SEM. *p < 0.05 (Student’s t test).
ormation assay following irradiation (IR) compared to unirradiated controls (C).
Cs treated with or without OPN for 24 hr alone or in the presence of 10 mMMK-
st three independent experiments. Error bars represent SEM. *p < 0.05; ns, not
ith 1,000 ng/ml OPN or 200 mM TPA (positive control for CD44ICD) or 200 mM
4EXT is CD44 cleaved extracellularly but still membrane bound. Right graph
*p < 0.05 (Student’s t test).
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Figure 3. The CD44 Intracellular Domain Promotes Aggressive Growth in a Mouse Model of Proneural GBM
(A) CD44 C-terminal staining by IHC onmurine PDGFB-induced gliomas. Left panel shows nuclear staining (black arrow), middle panel showsmembrane staining
(white arrow), and right panel shows cytoplasmic staining (gray arrow).
(B) Schematic overview of the CD44 gene and the EGFP CD44 intracellular domain (CD44ICD) fusion construct. SP, signal peptide; ECD, extracellular domain;
TM, transmembrane domain; ICD, intracellular domain.
(C) Expression of EGFP-CD44ICD in PIGPCs visualized by EGFP expression. Lower panels show nuclei by DAPI staining.
(D) CD44 C-terminal staining by IHC on murine gliomas induced by PDGFB in combination with RCAS-GFP or RCAS-CD44ICD as indicated. Graph shows
quantification of CD44 staining; average values for all tumors.
(E) Kaplan-Meier plot of survival for mice injected with RCAS-PDGFB in combination with RCAS-GFP (n = 8) or RCAS-CD44ICD (n = 6) as indicated. p = 0.02 (log-
rank [Mantel-Cox] test).
See also Figure S2.
Cell Stem Cell
CD44 Signaling in the Glioma Perivascular Niche(Figures S4C and S4D) and expressed EGFP or CD44ICD in
T98G cells andmeasuredHRE-luciferase activity in the presence
of DIP. Interestingly, in EGFP-expressing cells, knockdown of
CBP had no effect on HRE-luciferase activity, whereas p300
knockdown significantly decreased the HRE-luciferase signal
(Figure 6C). Strikingly, however, both CBP and p300 siRNA
significantly blunted the increase in HRE-luciferase activity
induced by CD44ICD (Figure 6C). Thus, CD44ICD potentiates
HIF-2a signaling in a CBP/p300-dependent manner.
We next asked to what extent HIF-2a mediated CD44ICD-
induced gene expression changes globally and performed
microarray analysis on T98G TetOn-CD44ICD cells treated
with or without Dox and transfected with either nontargeting
control or HIF2A siRNA. Strikingly, principal component analysis
(PCA) mapping showed that whereas control-siRNA-transfected
samples grouped separately based on CD44ICD expression,
there was essentially no difference between groups in the
HIF2A-siRNA-transfected cells (Figure 6D). These data suggest362 Cell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc.that the vast majority of CD44ICD-induced gene expression
changes are mediated by HIF-2a.
CD44 Is Differentially Expressed across GBM Subtypes
and Correlates with Short Survival in Proneural GBM
Finally, we stained a series of human GBM samples for CD44
protein expression by IHC and divided them according to their
expression profile into the proneural, mesenchymal, or classical
GBM subtype (Phillips et al., 2006; Verhaak et al., 2010).
Whereas mesenchymal and classical tumors expressed CD44
at high levels throughout the tumor, CD44 expression in proneu-
ral tumors was restricted to the PVN (Figures 7A–7C), similar to
CD44 expression in our murine PDGF-induced gliomas (Fig-
ure 1A). We queried the data set on humanGBM from the Cancer
Genome Atlas Network (CGA) (Cancer Genome Atlas Research
Network, 2008) for CD44 gene expression and found that
patients with low levels of CD44 survived significantly longer
than those with normal levels (Figure 7D). Interestingly, although
Figure 4. CD44ICD Promotes a Stem-like Phenotype in Glioma Cells
(A) SP analysis of T98G cells and PIGPCs expressing EGFP or EGFP-CD44ICD. Inset shows FTC-treated control sample. Right graphs show relative SP from at
least three separate experiments.
(B) SP analysis of PIGPCs expressing EGFP or EGFP-CD44ICD treated with control or CD44 blocking antibodies for 72 hr prior to analysis. Right graph shows
relative SP from at least three separate experiments.
(C) qPCR data for relative mRNA expression of Nanog, Sox2, Oct4, and Id1 in PIGPCs expressing EGFP control or EGFP-CD44ICD. Data represent average
values of at least three independent experiments. Error bars represent SEM. *p < 0.05 (Student’s t test).
(D) qPCR data for relative mRNA expression of NANOG, SOX2, OCT4, and ID1 in primary human GBM control cells or EGFP-CD44ICD-expressing cells. Data
represent one representative experiment out of at least three independent experiments. Error bars represent SEM. *p < 0.05 (Student’s t test).
(legend continued on next page)
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between CD44 expression and aggressive glioma growth held
true only in the proneural group of GBM, with no survival differ-
ence between groups in other subtypes (Figure 7D). We tested
the hypothesis that CD44ICD expression shifted proneural
GBM cells toward a mesenchymal phenotype. Although some
hallmark genes of the mesenchymal subtype like Stat3 were
indeed induced by CD44ICD, others were not (Figure S6), sug-
gesting that CD44ICD is not sufficient to drive the mesenchymal
phenotype.
To investigate the relation between CD44 and hypoxia-
induced gene expression in GBM in vivo, we ranked genes in
the CGA data set on GBM according to their correlation with
CD44 and then performed gene set enrichment analyses
(GSEA) specifically for gene sets associated with hypoxia.
CD44-correlated genes showed highly significant enrichment
for four different published gene sets upregulated by hypoxia
in independent systems (Figure 7E), establishing a link between
CD44 expression and hypoxia-induced gene expression in gli-
oma, consistent with our finding that CD44 signaling activates
gene expression through HIF-2a in human GBM in vivo.
DISCUSSION
Although CD44 was identified as a marker of mesenchymal
GBM (Phillips et al., 2006), previous work paradoxically estab-
lished that its expression can be used to isolate presumably
rare stem-like glioma cells (Anido et al., 2010). Here, we
confirmed high CD44 protein expression in mesenchymal
GBM and found high expression throughout the tumor also in
the classical subtype but, importantly, found restricted high
expression in perivascular cells in proneural GBM. These find-
ings suggest that the apparent paradox of CD44 can be
resolved by subdividing gliomas into molecular subtypes and
raise the possibility that CD44 expression highlights stem-like
cells from proneural GBM while serving as a general marker of
tumor cells in other subtypes. Bulk cells in proneural GBM
have an oligodendrocytic phenotype, and CD44 does not
seem to be generally expressed in this cell type. Stem-like tumor
cells, on the other hand, have a more mesenchymal phenotype,
including expression of CD44, and reside primarily in the PVN. In
other GBM subtypes, the tumor bulk consists of mesenchymal/
astrocytic cells that naturally express CD44 (in fact, we previ-
ously identified CD44 as a marker of tumor-associated stromal
astrocytes in proneural tumors; Katz et al., 2012). In light of
these expression patterns, it is intriguing that CD44 expression
correlated with poor prognosis in GBM only of the proneural
subtype. The correlation between aggressive tumor growth
and CD44 expression appears causal in this tumor type,
because Cd44/ and Cd44+/ mice survived significantly
longer than Cd44+/+ mice in a mouse model of proneural GBM
and CD44ICD overexpression promoted aggressive growth in
the same model.(E) qPCR data for relative mRNA expression of NANOG, SOX2, OCT4, and ID
representative experiment out of at least three independent experiments. Error b
(F) qPCR data for relative mRNA expression of NANOG, SOX2, OCT4, and ID1
values of at least three independent experiments. Error bars represent SEM. *p <
(G) Fraction survival of T98G control or EGFP-CD44ICD-expressing cells in a co
364 Cell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc.The perivascular region is recognized as a niche for stem-like
tumor cells in several brain tumors; cells surviving irradiation
in medulloblastoma are almost exclusively perivascular, and
stem cell markers appear enriched in the PVN (Calabrese
et al., 2007; Hambardzumyan et al., 2008). It is expected that
niche-derived factors actively maintain the stem-like state of
adjacent tumor cells. For example, we have previously shown
that endothelial cell-derived nitric oxide can activate Notch
signaling and promote stemness in glioma cells (Charles et al.,
2010). Here, we identify OPN as a factor expressed exclusively
in the PVN in proneural GBM. OPN stimulated the SP, stem
cell marker expression, and radiation resistance in glioma cells;
thus, OPN appears to be one niche-derived factor promoting the
stem-like phenotype of PVN glioma cells. We recently identified
SPP1 (encoding OPN) as the most upregulated gene in tumor-
associated stromal astrocytes of the PVN as compared to
normal brain astrocytes in a mouse model of proneural GBM
(Katz et al., 2012). It is thus possible that stromal astrocytes in
the PVN indirectly confer radiation resistance and stemness on
glioma cells through secretion of OPN and may conceivably
serve as nontransformed therapeutic targets. Tumor stemness
is frequently viewed as a package comprising stem cell marker
expression, drug/radiation resistance, and increased tumorige-
nicity in vivo, factors that have indeed been shown to be coregu-
lated by niche factors like nitric oxide in the glioma PVN (Charles
et al., 2010). Although our study revealed increased stem cell
marker expression, SP phenotype, and radiation resistance,
we found no increase in tumorigenicity of cells transiently pre-
treated with OPN. These findings are in line with recent advances
separating self-renewal and stemness from tumorigenicity spe-
cifically in glioma (Barrett et al., 2012) and point to the need of
separate consideration of all these factors.
Release of the CD44ICD by g-secretase in tumor cells is well
described (Nagano and Saya, 2004; Okamoto et al., 2001), but
its consequences thus far are incompletely understood. OPN
expression has been shown to correlate with intracellular
CD44 in tumor material in vivo (Hsu et al., 2010). Here, we pre-
sent data demonstrating that OPN induced CD44ICD genera-
tion in human glioma cells. Furthermore, effects on some
stem cell marker expression by OPN were abolished by g-sec-
retase inhibition, strongly supporting that OPN effects can be
mediated by CD44ICD. Previous in vitro experiments have
hinted at an active role for CD44ICD in tumor biology. For
instance, CD44ICD was shown to promote neoplastic transfor-
mation of rat fibroblasts (Pelletier et al., 2006), and CD44ICD
sustains proliferation of thyroid cancer cells (De Falco et al.,
2012). Here, we show that expression of CD44ICD together
with PDGF in a mouse model of proneural GBM resulted in
more aggressive tumor growth and shorter survival as
compared to control mice, thus identifying CD44 cleavage as
a potential therapeutic target in human cancer. These data
demonstrate tumor-promoting effects of CD44ICD in an in vivo
model of any tumor type.1 in U251 control or EGFP-CD44ICD-expressing cells. Data represent one
ars represent SEM. *p < 0.05 (Student’s t test).
in T98G control or EGFP-CD44ICD-expressing cells. Data represent average
0.05; ns, not significant (Student’s t test).
lony formation assay at day 7 following irradiation.
Figure 5. CD44ICD Promotes Stemness by Enhancing HIF-2a Activity
(A) Relative HRE-luciferase normalized to Renilla for T98G cells expressing EGFP control or EGFP-CD44ICD, with or without 200 mMDIP for 24 hr. Data represent
mean values from at least three independent experiments. Error bars represent SEM. ***p < 0.001; ns, not significant (Student’s t test).
(B) Relative HRE-luciferase normalized to Renilla for U251 cells expressing EGFP control or EGFP-CD44ICD, with or without 200 mMDIP for 24 hr. Data represent
one representative experiment out of at least three independent experiments. Error bars represent SEM. *p < 0.05, ***p < 0.001 (Student’s t test).
(C) Relative HRE-luciferase normalized to Renilla for primary humanGBM cells expressing EGFP control or EGFP-CD44ICD, with or without 200 mMDIP for 24 hr.
Data represent one representative experiment out of at least three independent experiments. Error bars represent SEM. *p < 0.05; ns, not significant (Student’s
t test).
(D and E) Relative HRE-luciferase normalized to Renilla for T98G (D) and U251 (E) cells expressing EGFP control or EGFP-CD44ICD coexpressed with pcDNA
(empty vector), HIF-1a, or HIF-2a as indicated. Data represent one representative experiment out of at least three separate experiments. Error bars represent
SEM. *p < 0.05, ***p < 0.001; ns, not significant (Student’s t test).
(F) Relative HRE-luciferase normalized to Renilla for U251 cells expressing EGFP or CD44ICD as indicated and transfectedwith control or siRNAs targetingHIF1A
or HIF2A as indicated. *p < 0.05, ***p < 0.001; ns, not significant (Student’s t test).
(legend continued on next page)
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Figure 6. CD44ICDPotentiates HIF-2a in a CBP/p300-DependentManner andHIF-2aAccounts for Global Transcriptional Effects of CD44ICD
(A) qPCR analysis of HIF2A in T98G TetOn-CD44ICD cells treated with DIP (hypoxia) or Dox (CD44ICD) as indicated. Data represent average values of at least
three independent experiments. Error bars represent SEM.
(B) Western blot analysis of HIF-2a and actin in T98G TetOn-CD44ICD cells treated with DIP (hypoxia) or Dox (CD44ICD) as indicated.
(C) Relative HRE-luciferase normalized to Renilla for T98G cells expressing EGFP control or EGFP-CD44ICD, transfected with control or siRNAs targetingCBP or
p300 as indicated. Data represent one representative experiment out of at least three separate experiments. Error bars represent SEM. *p < 0.05; ns, not
significant (Student’s t test).
(D) PCAmapping of T98G TetOn-CD44ICD cells treated with or without Dox and transfected with siRNA targetingHIF2A or control as indicated. Circles represent
controls and squares represent Dox-treated samples. Red indicates siControl-transfected samples and blue indicates siHIF2A-transfected samples.
See also Figure S5.
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CD44 Signaling in the Glioma Perivascular NicheCD44 was recently shown to increase stemness in colon can-
cer cells in a process dependent on the C-terminal end of CD44
(Su et al., 2011). We show here that CD44ICD is sufficient to
induce some stemness and radiation resistance in a subset of
glioma cells on its own. Mechanisms of CD44ICD signaling up
to this point have been incompletely understood. Saya and col-
leagues described that transcription dependent on CBP/p300
was enhanced by CD44ICD expression (Okamoto et al., 2001).
Our finding that CD44ICD enhances HIF-dependent transcrip-
tion is consistent with a general enhancement of CBP/p300-
dependent transcription, although further studies are needed
to understand how specificity for either HIF is achieved.
Recently, a CD44ICD-responsive element (CIRE) was identified
in the promoters of some genes activated by CD44ICD overex-
pression (Miletti-Gonza´lez et al., 2012). Interestingly, such
sequences were frequently found in genes also containing
HREs. Experimental and CGA data presented here support
that CD44ICD induces genes with HREs in GBM; however, we
demonstrate that CD44ICD activation of gene expression is
dependent on HIF-2a, because HIF2A knockdown diminished
any effects of CD44ICD on the specific target genes investigated
here. It appears unlikely that binding of CD44ICD to CIREs is
involved in this process, because CD44ICD could enhance
HIF-2a activation of HREs in a reporter construct lacking any(G) qPCR data for relative mRNA expression of NANOG, SOX2, OCT4, and ID1
and transfected with control or HIF2A-targeting siRNAs. Data represent average
*p < 0.05; ns, not significant (Student’s t test).
(H) qPCR data for relative mRNA expression of VEGF in T98G TetOn-CD44ICD ce
HIF2A-targeting siRNAs. Data represent average values of at least three indepen
(I) SP analysis of T98G TetOn-CD44ICD cells treated with or without Dox (CD44IC
treated control sample. Graph shows relative SP from at least three separate ex
See also Figures S3 and S4.
366 Cell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc.flanking CIREs. Furthermore, we did not find any CIREs in the
promoter region of SOX2 (data not shown). Differences between
CD44ICD-induced genes between cell lines, where applicable,
were largely reflected in differences between hypoxia-induced
genes, further supporting that CD44ICD signals mainly through
this pathway (Figure S7). Importantly, microarray analysis indi-
cated that the vast majority of CD44ICD-mediated gene expres-
sion changes globally in our system were dependent on HIF2A,
because there was no apparent difference between CD44ICD-
expressing and control cells in PCA mapping when HIF2A was
knocked down by siRNA. It should be noted, however, that at
least under some experimental conditions, we found potentia-
tion of HRE activation also by exogenous HIF-1a, suggesting
that CD44ICD under certain circumstances may signal through
both HIFs.
Our study supports recent findings indicating a crucial role
for HIF-2a in maintaining glioma stemness (Bar et al., 2010; Li
et al., 2009; Pietras et al., 2010; Soeda et al., 2009). Hypoxic
conditions were first shown to induce dedifferentiation of tumor
cells in neuroblastoma (Jo¨gi et al., 2002). Similar findings have
since supported this idea in other tumor forms and often impli-
cated HIF-2a as a driver of this phenomenon (Keith and Simon,
2007; Mathieu et al., 2011; Pietras et al., 2010). Mechanisms
involved include direct transcriptional activation or potentiationin T98G TetOn-CD44ICD cells treated with DIP (hypoxia) or Dox (CD44ICD)
values of at least three independent experiments. Error bars represent SEM.
lls treated with DIP (hypoxia) or Dox (CD44ICD) and transfected with control or
dent experiments. Error bars represent SEM. ns, not significant.
D) and transfected with control or HIF2A-targeting siRNAs. Inset shows FTC-
periments.
Figure 7. CD44 Is Differentially Expressed across GBM Subtypes and Correlates with Poor Survival in Proneural Tumors
(A–C) CD44 staining by IHC on human GBMs subdivided by their molecular subtype as indicated.
(D) Kaplan-Meier plots of human GBM specimens from the CGA data set (487 patients) based on low versus normal gene expression of CD44, grouped by GBM
subtype (128 proneural, 149 mesenchymal, 79 neural, and 131 classical). p values calculated by log-rank (Mantel-Cox) test.
(E) GSEAs carried out on a CD44-correlated ranked gene list produced from the GBMCGA data set. Enrichment was observed for the indicated hypoxia-related
gene sets (Winter_hypoxia_metagene normalized enrichment score [NES] = 2.63, FDR q = 0.000; Elvidge_hypoxia_up NES = 2.54, false discovery rate [FDR]
q = 0.000; Harris_hypoxia NES = 2.53, FDR q = 0.000; Manalo_hypoxia_up NES = 2.36, FDR q = 0.000).
See also Figure S6.
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CD44 Signaling in the Glioma Perivascular Nicheof activity of pluripotency factors by HIF-2a (Covello et al.,
2006; Gordan et al., 2008). HIF-2a is further expressed at
high levels in the PVN of brain and other neural tumors (Li
et al., 2009; Pietras et al., 2008), a counterintuitive finding sup-
ported by the seemingly aberrant stabilization of HIF-2a under
normoxic conditions specifically in glioma stem-like cells (Li
et al., 2009).
Finally, our findings raise the possibility that CD44 via its intra-
cellular domain plays a more active role than previously antici-
pated in stem cell biology in the wide variety of tissues and
cancers where CD44 is regarded as a stem cell marker. Particu-
larly, those cases where g-secretase inhibition or HIF expression
has profound effects on differentiation states warrant more care-Cful investigation into relative contributions of the Notch andCD44
pathways.EXPERIMENTAL PROCEDURES
Generation of Murine Gliomas with RCAS/tv-a
Gliomas were induced in Nestin-tv-a (Ntv-a) mice by injecting RCAS-PDGFB-
transfected DF-1 cells (ATCC) intracranially in the neonatal brain as previously
described (Holland et al., 1998).Cd44+/ andCd44/micewere generated by
crossing Ntv-a Cd44+/+ mice with Cd44/ mice (Jackson Laboratory) and
backcrossing at least sevengenerations.Miceweremonitoreddaily andeutha-
nized upon symptoms of glioma (lethargy and enlarged skull, tilted head). All
procedureswereapprovedby the Institutional AnimalCareandUseCommittee
at Memorial Sloan-Kettering Cancer Center (protocol# 00-11-189).ell Stem Cell 14, 357–369, March 6, 2014 ª2014 Elsevier Inc. 367
Cell Stem Cell
CD44 Signaling in the Glioma Perivascular NicheQuantitative Real-Time PCR
RNA was isolated using QIAzol and the RNeasy mini kit (QIAGEN), and cDNA
was synthesized using the Superscript III First-Strand Synthesis kit (Invitrogen)
according to manufacturers’ recommendations. Quantitative PCR was per-
formed using a 7900HT Fast Real Time PCR system and SYBR green (both
Applied Biosystems) using primers listed in the Supplemental Experimental
Procedures. Relative gene expression was normalized to the expression of
two housekeeping genes (UBC and SDHA) using the comparative Ct method
(Vandesompele et al., 2002).
Side Population, Luciferase, and Colony-Formation Assays
For SP, cells were resuspended at 13 106 cells/ml and then incubated at 37C
for 30 minutes with or without Fumitremorgin C (FTC) (Sigma). Cells were then
incubated for a further 90 minutes with 5 mg/ml Hoechst 33342 with periodic
shaking. Hoechst 33342 was excited at 407 nm using a trigon violet laser,
and dual wavelength detection was performed using 450/40 (Hoechst
33342-blue) and 695/40 (Hoechst 33342-red) filters. For the luciferase reporter
assay, cells were cotransfected with HRE-luc (Emerling et al., 2008; Addgene
#26731) and pCMV-renilla (Promega) and then analyzed for luciferase using
the Dual-Luciferase Reporter Assay System (Promega) on a Veritas luminom-
eter (Turner Biosystems). For the colony-formation assay, cells were plated at
clonal density in six-well plates and then irradiated. Colonies were fixed and
manually counted at day 10 postirradiation.
Plasmids
Human CD44ICD was amplified from pBabe-CD44S (Godar et al., 2008)
(Addgene #19127) and then subcloned into pEGFP-C1 (Clontech). The result-
ing fusion gene was further subcloned into RCAS-Y. The TetOn Dox-inducible
cells were generated using the Retro-X TetOn system (Clontech). The HRE-
luciferase plasmid was previously described (Emerling et al., 2008) (Addgene
#26731). Oxygen-insensitive mutants of HIF1A and HIF2A (Yan et al., 2007)
were obtained from Addgene (#18955 and #18956, respectively).
Affymetrix and CGA Data Analysis
The CGA data set on GBM (540 patients) was analyzed using the cBioPortal
(http://www.cbioportal.org) with annotated CGA data. CD44 and SPP1
expression 1 SD lower than average was considered low. GSEA was per-
formed using software and data sets available at http://www.broadinstitute.
org/gsea/index.jsp. Hypoxia-related gene sets were previously described
(Elvidge et al., 2006; Harris, 2002; Manalo et al., 2005; Winter et al., 2007).
Affymetrix expression arrays (U133A) were performed by the Memorial
Sloan-Kettering Cancer Center Genomics core facility, and data were
analyzed using Partek Genomics Suite.
Statistical Analysis
Statistical significance was calculated by indicated unpaired and two-sided
tests using GraphPad/Prism.
ACCESSION NUMBERS
The Array Express accession number for the microarray data reported in this
paper is E-MEXP-3914.
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Procedures and seven figures and can be foundwith this article online at http://
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